Comera Life Sciences (CMRA) Competitors $0.0002 0.00 (0.00%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CMRA vs. SCPS, EVLO, GNCAQ, GNCA, ARDS, STAB, AMPE, EFTR, HSTO, and ONCSQShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Its Competitors Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Histogen OncoSec Medical Scopus BioPharma (NASDAQ:SCPS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Does the media prefer SCPS or CMRA? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Comera Life Sciences Neutral Is SCPS or CMRA more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Comera Life Sciences N/A N/A N/A Which has stronger valuation & earnings, SCPS or CMRA? Scopus BioPharma has higher earnings, but lower revenue than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AComera Life Sciences$1.00M0.01-$18MN/AN/A Which has more volatility & risk, SCPS or CMRA? Scopus BioPharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. SummaryComera Life Sciences beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$752.17M$5.57B$9.31BDividend YieldN/A4.84%4.23%4.03%P/E RatioN/A1.4328.6119.73Price / Sales0.0125.51411.31174.27Price / CashN/A19.5636.0257.96Price / BookN/A6.608.235.67Net Income-$18M-$4.53M$3.23B$257.79M7 Day PerformanceN/A1.40%-0.01%0.52%1 Month PerformanceN/A1.30%5.60%8.84%1 Year PerformanceN/A3.42%26.54%14.18% Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/AN/AN/A-99.8%$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020News CoverageAMPEAmpio PharmaceuticalsN/A$0.00-32.5%N/A-88.9%$3KN/A0.0020EFTReFFECTOR Therapeutics0.0771 of 5 stars$0.00flatN/A-99.7%$1KN/A0.0010HSTOHistogenN/A$0.00-33.3%N/A-83.3%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies SCPS Competitors EVLO Competitors GNCAQ Competitors GNCA Competitors ARDS Competitors STAB Competitors AMPE Competitors EFTR Competitors HSTO Competitors ONCSQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
